Although the reason is still unclear, several reports revealed that FGF23 is a strong predictor of adverse cardiovascular outcomes in patients with chronic kidney disease (CKD) [15–19], suggesting a contribution of FGF23 to type 4 CRS (chronic renal dysfunction leading to cardiovascular dysfunction). This evidence concerns the gene FGF23 and chronic kidney disease.